Labiotech.eu

Best in Biotech 26 Aug 2019

15 Bioart Exhibitions to Check Out This Fall

The beauty and complexity of biology makes it a fascinating subject for artists to explore. Here are 15 bioart exhibitions to check out that bask in the frontier of art and science. Science and art are often presented as opposites. However, that couldn’t be further from the truth. Creativity is essential for science to progress. […]

August 26, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Aug 2019

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

An experimental HIV therapy being developed by GSK spinoff ViiV Healthcare in partnership with Janssen has proven it is as effective when given every two months as when given once a month. “For the first time since the AIDS epidemic started more than 30 years ago, our study has demonstrated that it is possible to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 22 Aug 2019

French Biotech Withdraws US Application for its Living Biocide

The US Environment Protection Agency (EPA) has stated it cannot grant registration to a biocide developed by Lyon-based company Amoéba for water treatment in cooling towers. Amoéba’s shares on Euronext Paris went down by 30% on Tuesday following the announcement. The biocide treatment consists of a live strain of amoeba called Willaertia magna C2c Maky. This […]

August 22, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Aug 2019

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp & Dohme. As part of the agreement, MSD will provide research funding and make an equity investment in Themis Bioscience. In addition, Themis will be eligible to receive up to €200M in milestones, in addition to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

Nabriva story bacterial pneumonia antibiotic

News and Trends 20 Aug 2019

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […]

August 20, 2019 - 3 minutesmins - By Helen Albert

News and Trends 16 Aug 2019

First Potential Chlamydia Vaccine Shows Early Promise

A vaccine targeting the sexually transmitted infection chlamydia, which would be the first of its kind if approved, has proved safe and able to stimulate the immune system in a phase I trial. In the phase I trial, the vaccine was injected into 35 healthy women. Blood samples from the volunteers were then measured to […]

August 16, 2019 - 3 minutesmins - By Jonathan Smith

astrocyte alzheimers disease astronautx blood london

Startup Scout 16 Aug 2019

This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells

It’s time to go to London, UK, this week. The UK biotech AstronauTx is developing drugs that could slow the progress of Alzheimer’s disease by aiming at star-shaped cells in the brain called astrocytes. Mission: To develop small molecule drugs targeting astrocytes, whose inflammatory activity is linked to the development of Alzheimer’s disease. Alzheimer’s disease […]

August 16, 2019 - 4 minutesmins - By Jonathan Smith

News and Trends 15 Aug 2019

Swiss Scientists Upgrade CRISPR to Edit Many Genes at Once

A research group at ETH Zurich, Switzerland, has made it possible to edit hundreds of genes at once with CRISPR gene editing. CRISPR gene editing has revolutionized the biotech industry by providing an easy and quick way to genetically modify organisms. So far, however, CRISPR techniques have only managed to edit a maximum of seven […]

August 15, 2019 - 3 minutesmins - By Jonathan Smith

mallinckrodt regenerative medicine skin graft bioprinting skin

News and Trends 14 Aug 2019

Engineered Skin Shows Potential to Treat Burns in Phase I

Engineered skin tissue, developed as a regenerative medicine by the UK-US pharma company Mallinckrodt, has reduced the need for skin grafts in burns victims in a phase Ib trial. The phase I trial tested Mallinckrodt’s engineered skin treatment in 29 patients suffering from deep second degree burns. Patients with these burns have damage to the […]

August 14, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Aug 2019

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

The US company AskBio has acquired the Edinburgh-based Synpromics to pool their gene therapy technologies and produce inducible gene therapies that target particular organs or cells. AskBio specializes in developing viral vectors that carry gene therapies into cells, such as adeno-associated virus, whereas Synpromics develops DNA sequences called promoters that drive the expression of gene […]

August 13, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Aug 2019

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

The UK biotech Autolus’ shares have slumped as construction delays from a new manufacturing site have pushed back its CAR-T cell immunotherapy programs. Autolus is developing treatments for blood cancer that involve engineering patients’ own immune cells to kill cancer cells, known as autologous CAR-T cell immunotherapies. Earlier this year, Autolus licensed a new manufacturing […]

August 12, 2019 - 2 minutesmins - By Jonathan Smith

water pollution solutions pharem biotech sweden uppsala

Startup Scout 9 Aug 2019

This Biotech Cleans up Drugs from Sewage Using Enzymes

We’re visiting Uppsala, Sweden, this week. This city is home to Pharem Biotech, a company developing enzymes to break down drug residues contaminating wastewater. Mission: To remove drug residue from sewage water by developing enzymes that are modified to be 200 times more effective than natural enzymes. This technology could reduce the ecological and health […]

August 9, 2019 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

15 Bioart Exhibitions to Check Out This Fall

Two-Drug HIV Therapy Given Every 2 Months Proves Effective in Phase III

French Biotech Withdraws US Application for its Living Biocide

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

First Potential Chlamydia Vaccine Shows Early Promise

This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells

Swiss Scientists Upgrade CRISPR to Edit Many Genes at Once

Engineered Skin Shows Potential to Treat Burns in Phase I

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

Manufacturing Delays Set Back Autolus’ CAR-T Programs by Five Months

This Biotech Cleans up Drugs from Sewage Using Enzymes

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!